Skip to content

Application study for ultrasound-guided internal silver needle thermal therapy in the treatment of chronic myofasciitis

Application study for ultrasound-guided internal silver needle thermal therapy in the treatment of chronic myofasciitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021902
Enrollment
Unknown
Registered
2019-03-11
Start date
2019-04-01
Completion date
Unknown
Last updated
2019-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myofascitis

Interventions

Group 1:Ultrasound-guided internal thermal silver needle thermal therapy (5-needle/pain point)
Group 2:Intensive internal thermal silver needle thermal treatment
Group 3:Non-ultrasound guided internal thermal silver needle heat treatment (5 needle / pain point)
Group 4:Anti-inflammatory analgesic injection treatment

Sponsors

Department of Pain, Fuling Central Hospital, Chongqing
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. To meet the clinical diagnostic criteria of myofasciitis; 2. Excluding myofasciitis other causes such as tumors, infections or fractures; 3. Patients had not received other conservative or non-surgical treatment in the recent three months; 4. Patients agreed to participate in the experiment and willing to follow up for a long time after operation, and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with infectious lesions or history of steroid allergy; 2. Patients with severe diabetes, severe osteoporosis, malignant hypertension, malignant tumors and other contraindications that are not suitable to use shock wave therapy; 3. Patients undergoing local knee injection within 3 weeks; 4. Patients with severe diabetes mellitus, severe osteoporosis, malignant hypertension, malignant tumors, etc. Pregnant, lactating or recent family planning patients; 5. Patients with poor compliance, can not cooperate with the completion of the treatment process, or combined with other methods of treatment.

Design outcomes

Primary

MeasureTime frame
VAS;VAS;

Secondary

MeasureTime frame
ODI;Prostaglandin E2;Bradykinin;ODI;Prostaglandin E2;Bradykinin;

Countries

China

Contacts

Public ContactLi Fei

Fuling Central Hospital of Chongqing

305228543@qq.com+86 15330565156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026